systemic ALCL

October 9, 2017

Adcetris Induced Durable, Long-term Remission in Nearly Half of Large Cell Lymphoma Patients in Phase 2 Trial

News

More than half of patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL, a particularly aggressive type of lymphoma) who received Adcetris (brentuximab vedotin) during a pivotal Phase 2 ... Read more

September 11, 2017September 11, 2017

Advisory Agency Decision Will Make Lymphoma Therapy Adcetris More Accessible in UK

News

Britain’s national health service advisory agency has made a decision that will make Adcetris (brentuximab vedotin) more accessible as a treatment for an aggressive type of lymphoma. The National Institute for Health and ... Read more